Jefferies Raises Price Target on Bellicum Pharma (BLCM) to $22; Reiterates Buy

August 9, 2016 9:50 AM EDT
Get Alerts BLCM Hot Sheet
Price: $13.78 --0%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade BLCM Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following the company's 2Q earnings report. BLCM reported a Q2 GAAP EPS of ($0.61) vs. estimates of ($0.59).

Analyst Biren Amin commented, "BLCM reported 2Q financial results and provided a pipeline update. For BPX-501, BLCM provided add'l color on recently announced BPX-501 regulatory pathway for peds in the EU and provided a brief clinical update for the BP-004 trial which included 3 new rimiducid-tx cases of GVHD. The PIs for BPX-601 and BPX-701 are on track to begin shortly. Lastly, BLCM does not plan to move BPX-401 into the clinic due to the CD19 competitive landscape."

For an analyst ratings summary and ratings history on Bellicum Pharmaceuticals click here. For more ratings news on Bellicum Pharmaceuticals click here.

Shares of Bellicum Pharmaceuticals closed at $17.05 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment